7. Merck & Co.


7. Merck & Co.
2017 cancer sales: $4.11 billion
2024 cancer sales: $13.21 billlion
Rank change: None

Merck’s Keytruda may be stealing the immuno-oncology show these days, but the way Evaluate sees it, the New Jersey drugmaker will still be slated seventh in oncology sales when 2024 comes around.

On the other hand, that year, the pharma giant will register more than $9 billion higher in cancer sales than it did last year, and much of that increase will come thanks to the company’s PD-1 moneymaker.

As anyone who has been following the I-O race knows, lung cancer is the most competitive field for the new generation of cancer fighters, and that’s because it represents a mammoth market—and financial opportunity. Currently, Keytruda leads rivals from Bristol-Myers, AstraZeneca, Roche and the Pfizer-Merck KGaA team in that department, boasting two approvals in the front-line setting to their collective zero.

Keytruda has also impressed in plenty of other cancer types, winning green lights in cancers including head and neck, cervical, lymphoma and more. Its indications across nine collective cancer types will all chip in sales that’ll contribute to its forthcoming leap.

Keytruda won’t be doing all the legwork on its own, though. Merck recently struck a pair of deals to gain access to two promising therapies that it hopes will come up big. Last July, it laid out $8.5 billion for half-ownership of AstraZeneca PARP inhibitor Lynparza, and it followed up this March with a $5.8 billion deal for a 50% stake in Eisai’s Lenvima.

7. Merck & Co.

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.